Case Study: How the XtalPi Team Discovered a Selective, Novel Lead Series for Key Cancer Target SMARCA2
Mutations in SMARCA4 drive cancer dependency on SMARCA2, making SMARCA2 a key therapeutic target. XtalPi leveraged AI-powered discovery platform and Cryo-EM technology to overcome challenges in developing selective SMARCA2 inhibitors.
Our Key Results:
- Discovered a lead series with 20-fold selectivity for SMARCA2 over SMARCA4.
- Identified a unique SMARCA2 binding pocket at 2.9 Å resolution using Cryo-EM.
- Achieved 100% compound synthesis success through predictive models.